
Overview
Inventro is a company that explores the complexities of cellular functioning by integrating in-vitro cell-based assays with machine learning and artificial intelligence. They focus on drug development and personalized medicine, utilizing sophisticated data analysis alongside wet-lab experimentation. Their team includes experts in computational methodologies, cell biology, and biochemistry, driving innovation in scientific research.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
News

Cell death
Cell-death assays are crucial tools for drug discovery and development, providing insights into the mechanisms of programmed cell death and drug-induced cell death. By using these assays, researchers can assess the efficacy and safety of potential drug candidates, optimize drug dosages, and identify potential adverse effects. There are several types of cell death, including apoptosis,

Cell health assays
Cell health assays measure various cellular processes to provide insight into how and why cells proliferate or die. These are primary tools to assess the cytotoxicity of drug candidates or other compounds, analyze cellular parameters in various diseases including cancer, and study basic cellular processes. The selection of a specific cell health assay depends on

Cell toxicity
One of the main events that occur after cell death is the loss of membrane integrity, which allows chemicals or proteins to freely enter or exit the cell. Taking advantage of this phenomenon, we are able to evaluate the cytotoxicity of a given compound either by determining the exact number of dead cells stained with

Protein target prediction
Protein target prediction is a critical component of modern drug design and pharmaceutical research. Computational methods provide fast and cost efficient solutions for obtaining initial hypotheses in areas such as virtual screening, drug repurposing or side effects prediction. Their predictive value constantly increases, benefitting from exponential growth of available data and computer power. Currently, given

Protein targets
Our AI-driven model for protein target prediction is designed to support the fast-paced environment of drug discovery. Our model streamlines the prediction of compound activities across a broad spectrum of protein targets, enhancing the efficiency of virtual assays and screening processes. By facilitating the rapid evaluation of millions of compounds, it offers a significant advantage

Virtual assays - new service by Inventro
Responses from individual targets are grouped according to target class into virtual assays panels that mirror those widely used in in-vitro screening assays. For each compound they provide instant information concerning possible area of application, off-target prediction, as well as potential safety concerns. Protein kinases Kinase binding assays play a crucial role in drug design,
Industry
Bank accounts
Registered as a VAT taxpayer on 2023-03-01. Active
12 1090 2590 0000 0001 5233 9930
39 1090 2590 0000 0001 5233 9929
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 28, 2025 | Aid for research and development projects: industrial research | —— | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| May 28, 2025 | Aid for research and development projects: experimental development | —— | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-01-01 | Wysokoprzepustowa i wieloparametrowa platforma dla testowania kandydatów na leki i leków przy użyciu modeli nowotworów ex vivo | $2.1M$2,144,730 | Fundusze Europejskie dla Nowoczesnej Gospodarki |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board, the member of the management board is authorised independently to represent the company. In the case of a multi-member management board being appointed, joint action of two members of the management board or one member of the management board jointly with a commercial proxy is required to represent the company.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Michał Komorowski (46) | Shareholder of a joint-stock company, 48.5% | |
Tomasz Piotr Nowowiejski (57) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Biostat Research and Developmentsp. z o.o. | $50,225.77 | biostat.com.pl | ||
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | ||
| Orphinic ScientificS.A. | $42,972.42 | orphinic.com | ||
| CannamedaiS.A. | $28,203.90 | cannamedai.com | ||
| Medaisp. z o.o. | $22,311.83 | medai.pl | ||
| Detoxedsp. z o.o. | $11,972.37 | detoxed.pl | ||
| Instytut Produktusp. z o.o. | $10,221.64 | instytutproduktu.pl | ||
| AI4Isp. z o.o. | $8,770.79 | ai4i.pl | ||
| IncellvuS.A. | $6,985.93 | incellvu.pl | ||
| Fusiomicasp. z o.o. | $5,263.98 | fusiomica.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-17 | Share capital change (100,000.00 PLN → 100,165.00 PLN) | |
| 2026-08-07 | Address change (Ul. Hurtowa 4/7, 15-399, Białystok → Ul. Złota 2/19, 15-016, Białystok) | |
| 2023-03-02 | PKD change (Removed: 72.11; Added: 72.11.Z) | |
| 2023-02-08 | Entered in the register |
FAQ
Last updated: 2026-10-03